Ropinirole
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Ropinirole
- Pharmacist Assessment Report
- Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Ropinirole is a dopamine agonist originally used to treat restless legs syndrome and Parkinson disease. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with no registered clinical trials but 8 publications currently supporting this direction. These include one 2026 randomized trial report whose design could not be verified beyond its title, and one pediatric case report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Restless legs syndrome; Parkinson disease (the Canadian licence records contain no indication text) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 8 of 8) |
| Number of DINs | 8 (marketed: 8) |
| Recommended Decision | Hold (research question stage) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, ropinirole is a D2/D3 dopamine receptor agonist. Its efficacy in restless legs syndrome and Parkinson disease is established, and mechanistically it may be applicable to ADHD, which is associated with dopaminergic dysregulation.
ADHD and restless legs syndrome frequently occur together. The literature suggests they may share dopaminergic and iron-metabolism pathways. A 2005 review examined this association and discussed the potential value of treatments common to both conditions. A pediatric case report described a 6-year-old boy with ADHD and sleep disruption from probable restless legs. He responded poorly to methylphenidate, but ropinirole improved both his ADHD symptoms and his sleep.
A 2026 publication (PMID 42640474) appears to report a randomized, double-blind, placebo-controlled trial of ropinirole added to methylphenidate in 66 children and adolescents with ADHD over eight weeks. Only the title and part of the abstract were available, so the results and design have not been verified. The evidence is therefore graded conservatively pending full-text review.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42640474 | 2026 | RCT (inferred from title; unverified) | Eur Child Adolesc Psychiatry | Ropinirole added to methylphenidate vs placebo plus methylphenidate in 66 children and adolescents (6–17 years) with ADHD over 8 weeks; results not available in the abstract excerpt |
| 16218085 | 2005 | Review | Sleep | Reviews the association between restless legs syndrome and ADHD, possible shared mechanisms, and common pharmacological treatments |
| 18656214 | 2008 | Review | Rev Neurol | Overview of restless legs syndrome (affects 2–3% of Western populations); background rather than ADHD-specific evidence |
| 15866437 | 2005 | Case report | Pediatr Neurol | A child with ADHD and restless legs had a significant improvement in ADHD symptoms and sleep with ropinirole |
| 34182128 | 2021 | Preclinical | Pharmacol Res | Dopamine D4 receptor variants and α2A adrenoceptor interact; implications for impulse-control disorders and ADHD |
| 24992083 | 2014 | Clinical study (indirect) | Clin Neuropharmacol | Piribedil compared with pramipexole and ropinirole on vigilance in Parkinson disease with daytime sleepiness; not ADHD-specific |
| 17483695 | 2007 | Animal model | J Neuropathol Exp Neurol | Mouse model of restless legs syndrome combining A11 lesioning and iron deprivation |
| 30950895 | 2019 | Safety report | Cornea | Corneal edema in 3 patients exposed to dopaminergic agents |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02314053 | SPC-ROPINIROLE | Not listed | Not listed |
| 02314088 | SPC-ROPINIROLE | Not listed | Not listed |
| 02314061 | SPC-ROPINIROLE | Not listed | Not listed |
| 02314037 | SPC-ROPINIROLE | Not listed | Not listed |
| 02316870 | TEVA-ROPINIROLE | Not listed | Not listed |
Eight single-ingredient licences are currently valid, and none are cancelled. Only the first five are shown here.
Safety Considerations
- Disease-level contraindications (from the knowledge graph, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, hypotensive disorder, drug-induced dyskinesia, liver failure, psychotic disorder, schizophreniform disorder, schizoaffective disorder, and mental disorder.
- Drug Interactions: The interaction query returned 100 records. The ones graded Moderate include morphine (including liposomal morphine), opium, cimetidine, dronabinol, nabilone, obeticholic acid, and metoclopramide. Many other entries have an unclassified severity.
- Other signals from the literature: dopamine agonists, including ropinirole, have been associated with an increased risk of gambling disorder in a Swedish nationwide register study. Corneal edema has also been reported with dopaminergic agents. These are relevant for a pediatric ADHD population and for patients with impulse-control problems.
Please refer to the package insert for the full warnings and contraindications, because label text was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, and the ADHD–restless legs overlap, a pediatric case report, and a possible 2026 randomized add-on trial make this the most credible of the ten predictions. However, no registered trials were provided, the key randomized study is unverified, and the safety and label data are incomplete. This candidate should stay at the research-question stage until the full text is reviewed.
To proceed, the following is needed:
- Full-text review of PMID 42640474 to confirm its design, sample size, primary outcomes, results, and adverse events
- Health Canada package insert warnings, contraindications, and approved indication text, since the licence records had none
- Detailed mechanism of action data from DrugBank
- A search of clinical trial registries for ropinirole in ADHD
- A pediatric safety assessment covering impulse-control disorders, sleepiness, orthostatic hypotension, and psychiatric adverse effects
- A check of the drug interaction list against typical ADHD co-medications, such as stimulants
The other nine predictions have no supporting trials, and most have no literature at all. The faciodigitogenital syndrome, polymicrogyria, retinal dystrophy, X-linked myopia, glycosylation disorder, glycine encephalopathy, and Charcot-Marie-Tooth predictions should remain on Hold. Schizophrenia also remains on Hold because the evidence is preclinical or indirect, and a dopamine agonist could worsen psychosis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.